To evaluate the potential of continuous glucose monitoring (CGM) for diagnosing gestational diabetes mellitus (GDM) and its association with specific pregnancy outcomes such as maternal and neonatal health.
Key Findings:
CGM metrics differentiated patients who developed GDM from those who did not, with statistical significance.
Higher mean glucose levels and greater glucose variability were observed as early as 13 to 14 weeks’ gestation in patients later diagnosed with GDM.
CGM-derived glucose patterns were linked to adverse neonatal outcomes, including large-for-gestational-age infants and neonatal hypoglycemia.
Some studies indicated CGM-detected glucose excursions correlated better with birth weight centiles than standard OGTT testing.
Randomized trials showed mixed results regarding CGM's impact on clinical outcomes, with some showing benefits and others not.
Interpretation:
While CGM shows promise in identifying GDM and correlating with adverse outcomes, it has not been validated as a replacement for OGTT due to differences in measurement and the urgent need for standardized diagnostic thresholds.
Limitations:
Reliance on observational data for diagnostic performance, which may not be generalizable.
Heterogeneity in study design and CGM devices, including variations in technology and methodology.
Lack of outcome-based diagnostic thresholds, which complicates clinical application.
Many randomized trials were not powered to detect differences in clinical outcomes, limiting the strength of the findings.
Conclusion:
CGM may complement existing screening strategies but requires further validation in randomized controlled trials before being used diagnostically. Current evidence is insufficient to support CGM as a standalone diagnostic test for GDM, highlighting the need for more robust studies.
Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.
Researchers linked several pregnancy urinary biomarkers—especially plasticizer and combustion-related chemical metabolites—to small shifts in gestational age and fetal growth measures in the ECHO Cohort.
